What is it about?
Everolimus (10 mg/day) got a significant reduction of renal angyolipomata size without serious untoward effects,
Featured Image
Why is it important?
Few prospective studies published.
Read the Original
This page is a summary of: Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial, Orphanet Journal of Rare Diseases, September 2016, Springer Science + Business Media,
DOI: 10.1186/s13023-016-0517-9.
You can read the full text:
Contributors
The following have contributed to this page
